Trends in development of self-complementary adeno-associated virus vector

Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology

Volumn 25, Issue 5, 2009, Pages 658-664

  Lü, Yinghui ^a,b   Wang, Qizhao ^a,b   Xiao, Weidong ^a,c   Diao, Yong ^a,b   Xu, Rui'an ^a,b  

^a HUAQIAO UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Gene therapy; Hemophilia B; Recombinant adeno associated virus; RNAi; Self complementary

Indexed keywords

ADENO-ASSOCIATED VIRUS; PARVOVIRUS;

COMPLEMENTARY DNA; DNA; SINGLE STRANDED DNA;

ADENO ASSOCIATED VIRUS; ANIMAL; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HEMOPHILIA B; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; REVIEW;

ANIMALS; BASE SEQUENCE; DEPENDOVIRUS; DNA; DNA, COMPLEMENTARY; DNA, SINGLE-STRANDED; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMOPHILIA B; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 77649216600     PISSN: 10003061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Xu RA, Chen L, Xiao WD. Molecular Gene Medicine. Beijing: Peking University Press and Peking University Medical Press, 2008: 2-40, 68-90.
2. During MJ, Xu RA, Young D, et al. Peroral gene therapy of lactose in tolerance using an adeno-associated virus vector. Nat Med, 1998, 4: 1131-1136.
3. Xu RA, Sun X, Tse LY, et al. Long-term expression of angiostatin and suppression of liver metastatic cancer. Hepatology, 2003, 37(6): 1451-1461.
4. Xu RA, Harrison PM, Chen M, et al. Cytoglobin protects against damage-induced liver fibrosis. Mol Ther, 2006, 13(6): 1093-1100.
5. Wang J, Xie J, Lu H, et al. Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proc Natl Acad Sci USA, 2007, 104(32): 13104-13109.
6. de la Maza LM, Carter BJ. Molecular structure of adeno-associated virus variant DNA. J Biol Chem, 1980, 255(7): 3194-3203.
7. Hirata RK, Russell DW. Design and packaging of adeno-associated virus gene targeting vectors. J Virol, 2000, 74: 4612-4620.
8. Gonçalves MA. Adeno-associated virus: From detective virus to effective vector. Virol J, 2005, 2: 43.
9. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther, 2001, 8(16): 1248-1254.
10. McCarty DM, Fu H, Monahan PE, et al. Adeno-associated virus terminal repeat (TR) mutant generates selfcomplementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther, 2003, 10(26): 2112-2118.
11. Wu J, Zhao W, Zhong L, et al. Self-complementary recombinant adeno-associated viral vectors: Packaging capacity and the role of Rep proteins in vector purity. Hum Gene Ther, 2007, 18: 171-182.
12. Xu RA, Janson CG, Mastakov M, et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther, 2001, 8: 1323-1332.
13. Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: Impact of larger genomes on infectivity and postentry steps. J Virol, 2005, 79(1): 9933-9944.
14. Ding W, Yan Z, Zak R, et al. Second-strand genome conversion of adeno-associated virus type 2 (AAV-2) and AAV-5 is not rate limiting following apical infection of polarized human airway epithelia. J Virol, 2003, 77(13): 7361-7366.
15. Fu H, Muenzer J, Samulski RJ, et al. Self-complementary adeno-associated virus serotype 2 vector: Global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther, 2003, 8(6): 911-917.
16. Wang Z, Ma HI, Li J, et al. Rapid and highly efficient transduction by doublestranded adeno-associated virus vectors in vitro and in vivo. Gene Ther, 2003, 10: 2105-2111.
17. Lee HS, Shin OK, Kim SJ, et al. Efficient gene expression by self-complementary adeno-associated virus serotype 2 and 5 in various human cancer cells. Oncol Rep, 2007, 18(3): 611-616.
18. Kim SJ, Lee WI, Heo H, et al. Stable gene expression by self-complementary adeno-associated viruses in human MSCs. Biochem Bioph Res Commun, 2007, 360(3): 573-579.
19. Han Z, Berendzen K, Zhong L, et al. A combined therapeutic approach for pyruvate dehydrogenase deficiency using self-complementary adeno-associated virus serotype-specific vectors and dichloroacetate. Mol Genet Metab, 2008, 93(4): 381-387.
20. Nathwani AC, Cochrane M, McIntosh J, et al. Enhancing transduction of the liver by adeno-associated viral vectors. Gene Ther, 2009, 16(1): 60-69.
21. Maina N, Han Z, Li X, et al. Recombinant self-complementary adeno-associated virus serotype vector-mediated hematopoietic stem cell transduction and lineage-restricted, long-term transgene expression in a murine serial bone marrow transplantation model. Hum Gene Ther, 2008, 19(4): 376-383.
22. Thomas CE, Storm TA, Huang Z, et al. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol, 2004, 78: 3110-3112.
23. Li G, Choi V, Bryant PA, et al. A new, non-imunogenic gene therapy vector for the human trabecular meshwork: scAAV (self-complementary adeno-associated virus). Invest Ophth Vis Sci, 2005, 46: 1358.
24. Buie LK, Borras T. New self-somplementary adeno-associated virus (scAAV) serotypes result in specific gene delivery to the trabecular meshwork in living rats. Invest Ophth Vis Sci, 2008, 49: 1610.
25. Petrs-Silva H, Min SH, Zhong L, et al. Improving retinal ganglion cell transduction by using scAAV type 8 or type 9 vectors containing capsid mutations. Invest Ophth Vis Sci, 2008, 49: 5350.
26. Nathwani AC, Gray JT, McIntosh J, et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 2006, 107(7): 2653-2661.
27. Hasbrouck NC, High KA. AAV-mediated gene transfer for the treatment of hemophilia B: Problems and prospects. Gene Ther, 2008, 15: 870-875.
28. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet, 1997, 16(3): 270-276.
29. Herzog R, Yang E, Couto L, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med, 1999, 5: 56-63.
30. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 2003, 101: 2963-2972.
31. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotype correction of hemophilia B dogs with a factor IX null mutation by liver directed gene therapy. Blood, 2002, 99(8): 2670-2676.
32. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAVFactor IX and limitations imposed by the host immune response. Nat Med, 2006, 12: 342-347.
33. Arruda VR, Schuettrumpf J, Herzog RW, et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood, 2004, 101(1): 85-92.
34. Hauck B, Xu R, Xie J, et al. Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia. Hum Gene Ther, 2006, 17(1): 46-54.
35. Gao GP, Lu Y, Sun X, et al. High-level transgene expression in nonhuman primate liver with novel adenoassociated virus serotypes containing self-complementary genomes. J Virol, 2006, 80(12): 6192-6194.
36. Nathwani AC, Gray JT, McIntosh J, et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood, 2007, 109(4): 1414-1421.
37. Wu Z, Sun J, Zhang T, et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther, 2008, 16(2): 280-289.
38. Wang QZ, Lü YH, Diao Y, et al. The design of vectors for RNAi delivery system. Curr Pharm Design, 2008, 14, 1327-1340.
39. Diao Y, Xu RA. Protocols of Cellular and Molecular Biotechnology. Beiing: Chemical Industry Press, 2008: 221-261.
40. Xu D, McCarty DM, Fernandes A, et al. Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol Ther, 2005, 11(4): 523-530.
41. Han ZC, Gorbatyuk M, Jr TJ, et al. Down-regulation of expression of rat pyruvate dehydrogenase E1alpha gene by self-complementary adeno-associated virus-mediated small interfering RNA delivery. Mitochondrion, 2007, 7(4): 253-259.
42. Kuznia PM, Glickman L, Yuan R, et al. Ribozyme mediated knockdown of TGF-β1 in cell culture using an scAAV vector. Invest Ophth Vis Sci, 2008, 49: E-Abstract 3385.
43. Maina N, Zhong L, Li X, et al. Optimization of recombinant adeno-associated viral vectors for human beta-globin gene transfer and transgene expression. Hum Gene Ther, 2008, 19(4): 365-375.
44. Han Z, Zhong L, Maina N, et al. Stable integration of recombinant adeno-associated virus vector genomes after transduction of murine hematopoietic stem cells. Hum Gene Ther, 2008, 19(3): 267-278.
45. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med, 2008, 358(21): 2240-2248.
46. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med, 2008, 358(21): 2231-2239.
47. Li H, Li XY, Xu RA. Adeno-associated vrus-mediated pancreatic and duodenal homeobox gene 1 delivery induced insulin-producing cells in livers of diabetic rats. Chin J Clin Pharmaco Ther, 2007, 12(6): 614-619.